Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 3/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | KDM4D | Q6B0I6 | 3/20 | 0.39 |
| ▸ | RET | P07949 | 4/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2179495 | 1.00 | CCR5 (0.42) | CCR5KCNA3KMT2AL3MBTL1KDM1A | |
| SCHEMBL2179498 | 1.00 | CCR5 (0.42) | CCR5KCNA3KMT2AL3MBTL1KDM1A | |
| SCHEMBL2178565 | 0.89 | MCHR1 (0.40) | CCR5KMT2ACTSKMCHR1 | |
| SCHEMBL2178560 | 0.89 | MCHR1 (0.40) | CCR5KMT2ACTSKMCHR1 | |
| SCHEMBL2178563 | 0.89 | MCHR1 (0.40) | CCR5KMT2ACTSKMCHR1 | |
| SCHEMBL2180562 | 0.87 | KDM4E (0.42) | KMT2ACTSKMCHR1 | |
| SCHEMBL2180567 | 0.87 | KDM4E (0.42) | KMT2ACTSKMCHR1 | |
| SCHEMBL2180563 | 0.87 | KDM4E (0.42) | KMT2ACTSKMCHR1 | |
| SCHEMBL2180550 | 0.86 | CHRNB2 (0.40) | CTSKRETDRD2MCHR1 | |
| SCHEMBL2180546 | 0.86 | CHRNB2 (0.40) | CTSKRETDRD2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2351738-A1 | PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO)PIPERIDIN-3-OL | Sumitomo Chemical Company, Limited (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20110172431-A1 | PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO) PIPERIDIN-3-OL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110166357-A1 | METHOD FOR PRODUCING N-SUBSTITUTED-TRANS-4-AZIDOPIPERIDINE-3-OL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166357-A1 | METHOD FOR PRODUCING N-SUBSTITUTED-TRANS-4-AZIDOPIPERIDINE-3-OL | RPS27L, OSGEP, RPLP1 | CCR5 3760/4885KCNA3 693/4885KMT2A 4049/4885 |
| US-20110172431-A1 | PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO) PIPERIDIN-3-OL | TEAD4, TEAD3, TEAD2 | CCR5 3447/4885KCNA3 501/4885KMT2A 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.